SEC Form 10-Q filed by Teva Pharmaceutical Industries Limited
$TEVA
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $35.00 | Overweight | Barclays |
| 12/5/2025 | $35.00 | Sector Outperform | Scotiabank |
| 6/6/2025 | $24.00 | Buy | Goldman |
| 5/28/2025 | $25.00 | Buy | Truist |
| 5/12/2025 | $23.00 | Neutral → Overweight | Analyst |
| 7/10/2024 | $20.00 | Hold → Buy | Argus |
| 3/8/2024 | $14.00 | Underweight → Neutral | JP Morgan |
| 2/12/2024 | $12.00 → $19.00 | Neutral → Overweight | Piper Sandler |
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC.UZEDY® revenues of $191 million, up 63% YoY in LC; underscoring Teva's commitment to drive new advances in neuroscience: Fastest growing long-acting injectable (LAI)1FDA expanded indicati
Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington's disease (HD) and chorea through Teva's Honestly HD programHD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson's and Alzheimer's, which manifests in motor, cognitive, and emotional symptoms1Teva's Honestly HD program provides educational information about HD chorea, a symptom occurring in up to 90% of people with HD,2 to help those living with the condition and their care partners better navigate its challenges PARSIPPANY, N.J., and TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients.1,2Results from the SPACE trial found AJOVY significantly reduced monthly migraine days and monthly headache days versus placebo over a 12-week period in pediatric patients with episodic migraine.1The U.S. Food and Drug Administration (FDA) approved AJOVY in August 2025 for the preventive treatment of episodic migraine in children and adolescents aged 6-17 years who weigh 45 kilograms (99 pounds) or more, building on its initial approval for the preventive treatment of migraine in
Barclays initiated coverage of Teva Pharma with a rating of Overweight and set a new price target of $35.00
Scotiabank initiated coverage of Teva Pharma with a rating of Sector Outperform and set a new price target of $35.00
Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem including in the U.S., Europe, Israel and beyond TEL AVIV, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today unveiled Teva Rise, a global open innovation platform designed to harness the power of a variety of disruptive tech
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC.UZEDY® revenues of $191 million, up 63% YoY in LC; underscoring Teva's commitment to drive new advances in neuroscience: Fastest growing long-acting injectable (LAI)1FDA expanded indicati
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva's Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (NASDAQ:RPRX), today announced a funding agreement of up to $500 million to accel
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the "Investors" page on its website. Q4 2025 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indu
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)